Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 8/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507420 | 0.91 | OPRM1 (0.44) | OPRM1OPRD1 | |
| SCHEMBL4516991 | 0.90 | — | — | |
| SCHEMBL4518648 | 0.90 | OPRD1 (0.47) | USP2OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4516858 | 0.88 | OPRM1 (0.40) | USP2OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4505597 | 0.87 | OPRM1 (0.40) | USP2OPRM1OPRD1OPRK1KCNH2 | |
| SCHEMBL4508136 | 0.81 | OPRM1 (0.54) | OPRM1OPRD1 | |
| SCHEMBL5197378 | 0.81 | OPRM1 (0.42) | OPRM1OPRD1OPRK1 | |
| SCHEMBL4511678 | 0.81 | MEN1 (0.40) | USP2OPRM1OPRD1KCNH2MEN1 | |
| SCHEMBL4513186 | 0.80 | MEN1 (0.38) | USP2OPRM1OPRD1MEN1KMT2A | |
| SCHEMBL5097094 | 0.80 | OPRM1 (0.44) | OPRM1OPRD1OPRK1KCNH2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | claimed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | claimed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135524-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | USP2 3363/4885OPRM1 4/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.